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We aimed to assess the effect of invasive group A 
streptococcal (GAS) infection and the potential effects 
of a multivalent GAS vaccine in New Zealand. During 
January 2005–December 2006, we conducted prospective 
population-based laboratory surveillance of Auckland 
residents admitted to all public hospitals with isolation of GAS 
from normally sterile sites. Using emm typing, we identiﬁ  ed 
225 persons with conﬁ  rmed invasive GAS infection (median 
53 years of age; range 0–97 years). Overall incidence was 
8.1 cases per 100,00 persons per year (20.4/100,000/
year for Maori and Paciﬁ   c Islanders; 24.4/100,000/year 
for persons >65 years of age; 33/100,000/year for infants 
<1 year of age). Nearly half (49%) of all cases occurred 
in Auckland’s lowest socioeconomic quintile. Twenty-two 
persons died, for an overall case-fatality rate of 10% (63% 
for toxic shock syndrome). Seventy-four percent of patients 
who died had an underlying condition. To the population in 
our study, the proposed 26-valent vaccine would provide 
limited beneﬁ  t.
D
uring the 2 decades since recognition of streptococcal 
toxic shock syndrome (STSS), there have been many 
publications on invasive group A streptococcal (GAS) 
infections, some population-based  (1–4). The spectrum 
of infection caused by Streptococcus pyogenes varies 
widely from invasive disease, such as bacteremia, sepsis, 
necrotizing fasciitis (NF), and STSS, to noninvasive 
infection, most commonly pharyngitis with suppurative 
complications, such as otitis media, and nonsuppurative 
complications, such as acute rheumatic fever (ARF) and 
acute glomerulonephritis (APSGN).
GAS infection causes a substantial number of illnesses 
and deaths, especially in the developing world, with 
≈500,000 deaths worldwide annually, attributable mostly to 
ARF and its sequelae, rheumatic heart disease, and invasive 
infection (5). GAS disease and its sequelae, including GAS 
pharyngitis, have been well documented in New Zealand 
(6–12; http://dnmeds.otago.ac.nz/departments/womens/
paediatrics/research/nzpsu/pdf/2008_report.pdf).
With renewed interest in GAS vaccines (13), 
understanding the complete spectrum of disease, including 
invasive GAS disease, in diverse populations is essential. 
The vaccine most completely studied is a 26-valent vaccine 
based on emm types and M subtypes collected across 
GAS diseases from the United States (14). We previously 
published a population-based approach of laboratory 
surveillance for invasive bacterial diseases in Auckland’s 
public hospitals where all persons with acute disease would 
be admitted (8,15–18). Using this approach, we demonstrate 
the effects of invasive GAS on the Auckland population 
to complement our knowledge of other GAS-associated 
diseases by using prospectively collected incidence data, 
clinical characteristics, associated underlying conditions, 
and the associated emm types. This study also provided 
an opportunity to establish the direction of further investi-
gations and to focus interventions in New Zealand.
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Methods
Surveillance
We enrolled patients during January 1, 2005–
December 31, 2006. Patients were included if they resided 
in metropolitan Auckland and had a GAS isolate cultured 
from a previously sterile body cavity. Patients with STSS 
were included in accordance with the consensus deﬁ  nition 
(19); STSS also was the diagnosis for patients who were 
dead on arrival or who died within 48 hours after illness 
onset and for whom laboratory data were insufﬁ  cient in 
accordance with the methodology of Davies et al. (1). NF 
was deﬁ  ned as tissue necrosis diagnosed by histopathologic 
examination or by the treating surgeon during surgical 
debridement. Patients could have had >1 diagnosis, with 
the exception of bacteremia without a source. Clinical 
syndromes, such as skin or soft tissue infection, had to be 
accompanied by recovery of an isolate from a normally 
sterile site or specimen, such as blood, to meet the case 
deﬁ   nition. Nosocomial infection was deﬁ   ned as GAS 
infection in patients who had been hospitalized for >72 
hours. Invasive GAS infection was deﬁ  ned as postpartum 
if it occurred in a woman who was pregnant or <30 days 
after delivery or who had clinician-deﬁ  ned  puerperal 
fever, chorioamnionitis, or a septic abortion. Women from 
whom GAS was isolated from amniotic ﬂ  uid or placenta 
alone were excluded (20). Our study was approved by the 
regional ethics committee and each hospital’s research 
committee and Maori research committee.
Data were collected from the microbiology laboratories 
serving all 3 Auckland regional District Health Board 
(DHB) hospitals, i.e., Auckland City Hospital and Starship 
Children’s Hospital (Auckland DHB); Middlemore 
Hospital, which includes Kidz First Children’s Hospital 
(Counties Manukau DHB); and North Shore Hospital 
and Waitakere Hospital (Waitemata DHB). All Auckland 
residents with serious medical illness would attend 1 of 
these hospitals.
Auckland (2006 population: 1,387,780), New 
Zealand’s largest city, comprises one third of the country’s 
population and is the country’s most ethnically diverse 
city. In 2006, 19.0% of residents self-identiﬁ  ed as Asian, 
14.4% as Paciﬁ  c Islander, 11.1% as indigenous Maori, and 
56.5% as European. The climate is temperate, with summer 
occurring during December through March. We used New 
Zealand birth data for infants <1 year of age and customized 
New Zealand census charts for DHBs as denominators.
We obtained demographic and clinical features by 
reviewing medical charts and electronic documents. To 
ensure complete surveillance, we requested International 
Classiﬁ  cation of Diseases, 10th Revision, diagnoses from 
DHB data managers. We contacted the regional coroner 
and forensic pathologist to seek out records of deaths 
(including deaths in the community) caused by GAS 
infection and scrutinized intensive care unit (ICU) data 
for diagnoses of shock from GAS, STSS, or NF. Disease 
severity was determined by length of stay, ICU admission, 
and use of surgical and medical procedures.
We assigned each invasive GAS infection in the 
Auckland region a deprivation score by using the New 
Zealand Deprivation Index 2006 (www.moh.govt.nz). 
This index measures socioeconomic status (SES) in small 
areas according to 9 variables (income, income assistance, 
education, access to a car and phone, household crowding, 
employment, single-parent family, housing rented or 
owned).
Laboratory Techniques
β-hemolytic colonies on blood agar were typed as 
Lanceﬁ  eld group A by using commercially available latex 
agglutination kits (Pro-Lab Diagnostics, Austin, TX, USA). 
Group A isolates were sent to Environmental Science and 
Research Laboratory (Wellington, New Zealand) for emm 
typing by using established procedures (21). Concordance 
between emm types and M serotypes has been established 
(21). Antimicrobial drug sensitivities were determined by 
routine methods (22).
Estimates of Vaccine Beneﬁ  t
We used emm typing to estimate the proportion of 
cases and deaths caused by emm types in the proposed 
26-valent vaccine. These emm GAS types are 1, 2, 3, 5, 6, 
11, 12, 13, 14, 18, 19, 22, 24, 28, 29, 33, 43, 59, 75, 76, 77, 
89, 92, 94, 101, and 114 (14). We then calculated potential 
vaccine efﬁ  cacy in the most at-risk Auckland populations: 
persons <5 years of age and >65 years of age.
Results
Epidemiology
During the 24-month study period, we identiﬁ  ed 333 
patients who potentially had invasive GAS infections. Of 
these, we excluded 118 who did not fulﬁ  ll the inclusion 
criteria. The most common reasons for exclusion were 
isolation from a nonsterile site or residence outside 
metropolitan Auckland at the time of diagnosis. Using 
the electronic discharge summaries based on International 
Classiﬁ   cation of Diseases, 10th Revision, coding, we 
identiﬁ  ed and included 10 (4%) additional cases that ﬁ  t the 
case deﬁ  nition.
The 225 patients were from all ethnic groups: European 
(77 [34%] patients), Maori (69 [31%]), Paciﬁ  c Islanders 
(70 [31%]), and other ethnicities (7 [3%]). For 2 patients, 
no information was available about ethnicity. For the 225 
patients, median age was 53 years (range 0–97 years), and 
119 (53%) patients were male. Ethnic disparities, although 
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notable in the extremes of life, did not differ signiﬁ  cantly 
by age (Figure 1; Table 1). The 198 patients with invasive 
GAS infection for whom SES information was available 
were more likely to originate in areas designated by the 
New Zealand Deprivation Index 2006 as lower SES areas 
than in higher SES areas (Table 2). Forty-nine percent of 
case-patients were from the lowest SES quintile.
Case-Fatality Rate
Twenty-two patients died, for an overall case-fatality 
rate (CFR) of 10% (Figure 1, Table 3). Fourteen of these 
patients died within 72 hours after hospital admission. Three 
infants (one 2 months of age and two 4 months of age) who 
died in the community had STSS. One death previously 
had been attributed to sudden infant death syndrome.
The median age of patients who died was 62 years 
(range 2 months–86 years). Eighteen adults who died had 
multiple concurrent illnesses. The highest CFR (31%) was 
for infants (a total of 4 deaths in three 4-month-old infants 
and one 2-month-old infant); these were the only deaths 
among children <15 years of age.
All infants who died had GAS-positive blood cultures. 
One who died in the community also had GAS-positive 
cerebrospinal ﬂ  uid. Three of the 4 deaths occurred in the 
community and are attributed to STSS. The illness of the 
fourth (hospitalized) infant also met the criteria for STSS. 
Bronchopneumonia was found at post-mortem examination 
in 2 infants (1 hospitalized, 1 in the community). Two of 
the infants who died in the community had additional 
pathogens isolated from postmortem blood cultures 
(Staphylococcus aureus in both cases and Streptococcus 
pneumoniae and viridans streptococci in 1 each) but no 
gram-negative organisms.
Clinical Features
The most common clinical feature was skin and soft 
tissue infection (97/225; 43%) (Table 3). Of the 30 patients 
with STSS, 26 (87%) had an underlying condition before the 
onset of acute GAS disease. Median age at STSS occurrence 
was 57 years (range 2 months–86 years). Six cases occurred 
in children <5 years of age. Empyema (4 cases; p<0.0001) 
and brain abscess (2 cases; p = 0.0011) occurred more 
frequently in children <14 years of age than in adults. The 
incidence of bacteremia with no focus of infection was 
1.4 cases per 100,000 persons per year overall, but 3.7 per 
100,000 for children <5 years of age (n = 7).
Seven cases of GAS postpartum infection were 
recorded for women 15–49 years of age, for a rate of 
0.16 cases per 1,000 live-born infants (Maori and Paciﬁ  c 
Islander, 0.21 cases/1,000 live-born infants). No deaths 
occurred in this group. We also identiﬁ   ed 3 premature 
neonates with invasive GAS disease unrelated to cases in 
adults; 1 infection was nosocomially acquired.
Risk Factors
Of the 223 patients for whom data were available, 58 
(26%) had no underlying condition or other risk factor, 114 
(51%) had 1 or 2 risk factors, and 64 (28%) had >3 risk 
factors. In the >15-years age group, 67 (35%) had heart 
disease, 60 (32% [23 Maori, 25 Paciﬁ  c Islanders]) had 
diabetes, and 21% had either renal disease (39 persons) or 
lung disease (40 persons). Cigarette smoking was the most 
common nondisease-related risk factor (56 [30%] of 189 
persons >15 years of age).
Microbiological Analysis and Potential 
Vaccine-Preventable Disease
GAS was most frequently isolated from peripheral 
blood cultures (184 [82%]). Other sources were surgical 
specimen (37 isolates), tissue specimen (18), joint 
aspirate  (16), pus aspirate (12), catheter blood culture 
(6), peritoneal aspirate (2), cerebrospinal ﬂ  uid (2), and 
postmortem blood (3).
Of the 225 cases, 205 (91%) GAS isolates were 
available for emm typing (Figure 2). Seventy (34%) of 205 
cases had an emm type that was contained in the 26-valent 
vaccine. The proposed 26-valent vaccine could prevent 
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Figure 1. A) Annual incidence rates for invasive group A 
streptococcal (GAS) disease, Auckland, New Zealand, 2005–
2006. The black line indicates age-speciﬁ  c case-fatality rates for 
combined ethnicities. B) Number of invasive GAS cases among 
infants <24 months of age. RESEARCH
30% of GAS invasive cases in children <5 years of age and 
15% of cases in persons >65 years of age (Table 4).
Of the 225 isolates, 1 (0.4%) was resistant to 
erythromycin and 1 (0.4%) had intermediate sensitivity to 
erythromycin. Three (1.3%) were resistant to clindamycin.
Disease Severity
Hospitalization was required for 222 patients (3 deaths 
occurred in the community). Length of stay was >10 days 
for 105 (47%); mean length of stay was 15.9 days (range 
1–153 days). Thirty-eight (17%) required ICU admission 
(mean length of stay 4.5 days; range 1–9 days); maximum 
length of stay was 19 days. Nosocomial infection was 
responsible for 12 (5%) of the 225 cases. Seventy-ﬁ  ve 
(33%) patients required at least 1 surgical procedure, 
predominantly drainage, débridement, or washouts. One 
patient (2 years of age) with STSS required intravenous 
immunoglobulin.
Discussion
Our New Zealand study is population based and 
prospective. The overall annual incidence rate for greater 
Auckland of 8.1 cases per 100,000 persons per year is more 
than double or triple the rate of earlier reports elsewhere 
in the industrialized world. Annualized rates reported from 
other industrialized countries were 3.5 per 100,000 in 2007 
in the United States (2); 1.5 in Ontario, Canada; and 3.1 in 
the Netherlands (1,23).
This study was conducted in metropolitan Auckland, 
where studies are ongoing to assess GAS disease, including 
endemic ARF (11,12,24), APSGN (http://dnmeds.otago.
ac.nz/departments/womens/paediatrics/research/nzpsu/
pdf/2008_report.pdf), and streptococcal pharyngitis (25) 
with associated emm typing. Our study was conducted 
in close association with ongoing active surveillance 
for ARF and its associated emm types (26) and APSGN 
surveillance. Our laboratory-based surveillance was 
supported by discharge data evaluation, chart review, and 
coroner surveillance, which minimized underestimation of 
STSS and NF. Approximately 50–70 new ARF cases (90% 
in persons <20 years) occur each year in this population 
(12,24) and a similar number of APSGN. The incidence of 
streptococcal pharyngitis has been carefully determined in 
a randomized controlled trial for ARF control at ≈60 cases 
per 100 child-years during a 4-year period in a population 
of ≈12,000 persons 5–19 years of age (11). This rate is 
considerably higher than that documented recently from 
Fiji (14.7/100 child-years) (27). Serotypes in ARF cases in 
our study were diverse (emm 58, 74, 75, 76, 92, 99, and 
53), mirroring an earlier report (emm 53 and 58 associated 
with ARF) (28).
The annualized rate for Maori and Paciﬁ  c Islanders <1 
year of age (75/100,000) was similar to rates reported from 
Kenya (29) and greater than the rate more recently reported 
from Fiji (44.9/100,000) (27) from prospective studies. 
Nearly 50% of cases occurred in the lowest SES quintile 
of Auckland. Indigenous Maori and Paciﬁ  c  Islanders 
are overrepresented in lower SES areas of Auckland. 
Ethnically disparate rates for invasive GAS parallel these 
ﬁ   ndings, with overrepresentation of these groups. The 
New Zealand Deprivation Index uses multiple parameters, 
including housing, income, and education. In addition, 
access to health care may be deﬁ  cient (30,31) and perhaps 
health knowledge as well. The role of crowded housing in 
the population in our study has been recently documented 
for epidemic meningococcal disease (32) and may have a 
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Table 1. Population-based incidence of invasive group A streptococcal disease, by age, Auckland, New Zealand, 2005–2006* 
Population
Age group, y 
<1 <15 <50 >65 All ages 
No. Rate No. Rate No. Rate  No. Rate  No. Rate 
Maori and Pacific Islander  11 20.3 27 13.0 74 80.1 30 113.0  139 20.4
 Maori  8 40.9 14 14.1 33 82.5 15 146.8  69 21.6
 Pacific  Islander  3 16.4 13 12.0 41 78.2 15 91.8 70 19.3
Other 2 4.1 9 2.4 53 8.9 36 15.0 84 5.3
Total 13 33.0 36 6.1 127 18.4 66 24.4 225 8.1
*Rate/100,000 population. Table includes only populations at risk. Use of a Poisson regression model indicated no evidence of a difference in the effect of 
ethnicity on risk in different age groups. The incidence rate ratios for all ages of Maori compared with others was 7.60 (95% confidence interval [CI] 5.10–
11.32) and for Pacific Islanders compared with others was 8.84 (95% CI 6.17–12.65). For male vs. female, the incidence rate ratio was 1.29 (95% CI 
0.96–1.74). 
Table 2. Invasive GAS infection and relation with socioeconomic 
status, Auckland, New Zealand, 2005–2006* 
New Zealand Deprivation 
Index 2006† 
No. (%) confirmed invasive GAS 
infections, n = 198 
10 63 (32) 
93 3 ( 1 7 )  
82 3 ( 1 2 )  
72 3 ( 1 2 )  
61 0 ( 5 )  
51 0 ( 5 )  
46 ( 3 )  
31 0 ( 5 )  
21 5 ( 8 )  
15 ( 3 )  
*Based on the 198 case-patients for whom socioeconomic status 
information was available. GAS, group A streptococcal. 
†New Zealand Ministry of Health, www.moh.govt.nz. 10, most deprived 
area; 1, least deprived area. Invasive Group A Streptococcal Infection
more substantial role for GAS disease, which is considered 
to be even more contagious (33). The high likelihood of 
an associated risk factor in the adult population, such as a 
chronic disease or another association, has been reported 
many times (1,2,27,34).
Skin infections have been documented as a major 
cause of illness in Auckland (35). More recently, New 
Zealand surveillance data (24) reported highly discrepant 
hospitalization rates for serious skin disease: Maori and 
Paciﬁ  c Islanders <15 years of age are more likely to be 
hospitalized (unadjusted rate ratios 2.77 [95% CI 2.66–
2.88] and 4.47 [95% CI 4.27–4.68], respectively) than are 
New Zealand European children 0–14 years of age. These 
data also reﬂ  ected more hospitalizations for persons living 
in the most deprived quintile (24), which most likely is 
related to poor access to primary care and perhaps health 
knowledge. High population-based rates of invasive 
disease caused by methicillin-sensitive S. aureus, mostly 
bone and joint disease, also have been documented (36).
The overall CFR from our study (10%), with a high CFR 
for STSS (63%), mirrors other studies in the industrialized 
world (2). This CFR suggests good access to hospital 
care and efﬁ  ciently delivered secondary and tertiary care, 
including ICU admission. A recently reported CFR (28%) 
from Fiji suggests otherwise from the developing world (27).
We included in our study all 3 infants who died in the 
community and from whom GAS was cultured (37). GAS is 
a rare ﬁ  nding from postmortem specimens (J. Zucollo, pers. 
comm.). In all 3 cases, only gram-positive organisms were 
isolated (1 solely group A streptococcus from blood and 
cerebrospinal ﬂ  uid). Studies in which careful precautions 
have been taken to reduce contamination show that 
approximately two thirds of blood cultures yield negative 
results, 2 in 9 yield 1 isolate, and 1 in 9 show mixed growth. 
GAS infection as the sole cause of death was less certain 
in 2 cases in our study in which >1 potentially disease-
causing species was cultured. We characterized the 3 infant 
deaths as STSS according to Davies et al. (1), a deﬁ  nition 
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Table 3. Clinical syndromes and CFRs for 225 patients with invasive GAS disease, Auckland, New Zealand, 2005–2006*  
Diagnosis†
Age group, y 
All ages, no. (%),‡ 
N = 225  p value§ 
0–14, n = 36  >15, n = 189 
No. CFR No. CFR 
Skin and soft tissue infection¶  11 0 86 8 97 (43)  0.14
Bacteremia only  7 38 31 19 38 (16)  0.63
STSS#** 6 67†† 24 54 30 (13) 0.59
Bone infection  6 0 20 0 26 (12)  0.39
Pneumonia and other respiratory infection  12 13 12 0 24 (11)  0.0001 
Necrotizing fasciitis**  1 0 19 15 20 (9)  0.21
Pelvic infection/peripartum‡‡  0 0 12 0 12 (5) 
*CFR, case-fatality rate; GAS, group A streptococcal; STSS, streptococcal toxic shock syndrome.  
†Patients may have had >1 diagnosis, with the exception of bacteremia without a source. Other conditions (not shown) included 4 upper airway infections 
6 ear/nose/throat infections, 5 central nervous system infections, 4 cases of peritonitis, 3 urinary tract infections, and 2 hemodialysis vascular access 
infections. No deaths occurred in this group. 
‡Overall CFR 10% (22/225). 
§p value calculated by using Fisher exact test, a test of difference between age groups. 
¶Includes cellulitis (n = 79), cutaneous abscess, boil, lymphadenitis, myositis, bursitis, infected burn, infected scabies, and infected ulcer with evidence of 
documented bacteremia. 
#STSS confirmed and probable (n = 3). 
**Five patients had STSS and NF; 1/5 died (20% CFR). 
††Three of 6 were community deaths in infants <1 y of age. 
‡‡Includes pregnancy-related (n = 6) endometritis and infected products, urinary tract infection/chorioamnionitis, and wound problems. 
Figure 2. The 25 most common 
emm types as a proportion 
of all isolates. The remaining 
emm types were as follows: 
100, 107, 25, 53, 56, 22, 18, 
103, 105, 106, 108, 112, 123, 
4, 51, 55, 70, 73, 77/27L, 
DRX4, ST6030, STN5554, 
109, 110, 12, 52, 77, 88, 97, 
ST4119, ST4547, and 76.RESEARCH
that produces higher rates of STSS and a higher CFR in 
children than in other reports. We look forward to further 
investigations in this area.
Current health strategies for preventing illness and 
death from invasive GAS infections are limited. The rate 
of nosocomial infection in our study was low. The high 
rates in postpartum women and in infants require further 
investigation. We were unaware of any links between cases 
in our series. In New Zealand, index cases of invasive GAS 
disease are not investigated by public health authorities 
(38). Primordial strategies, such as of the provision of less-
crowded housing (32) and hand-washing education, need 
further consideration (39).
The currently available vaccine most advanced in 
clinical trials (14) comprises 26 emm types representing 
population-based, practice-based, and historical 
assessments from the United States (14). Its applicability to 
the population in our study might be less than ideal. Thirty-
four percent of disease was caused by emm types in the 
proposed 26-valent vaccine. Data are accruing from other 
sites (79% emm coverage with the 26-valent vaccine in the 
United States, 69% in Europe, and 40% in Fiji) (4,14,27). 
Our data can contribute to a recent global estimate 
suggesting the current formulation of an experimental 
multivalent GAS vaccine may not be ideal in areas of most 
need (40). The effectiveness estimate in our study (Table 
4) suggests that fewer than one third of invasive GAS cases 
in children <5 years of age and perhaps 15% of cases in 
persons >65 years of age could be prevented. This ﬁ  nding 
is of particular concern in a New Zealand population where 
other GAS-associated diseases cause a substantial amount 
of illness and death.
The rates in our study, driven largely by high rates in 
indigenous Maori and Paciﬁ  c Islanders, are higher than 
those previously reported from industrialized countries and 
similar to reports from Fiji and Kenya. The rates suggest 
a need for more investigation and planned interventions 
in populations at highest risk. Our study also supports the 
role of GAS as a pathogen for invasive disease, particularly 
because of its effect on all age groups.
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Table 4. Invasive GAS disease and fatalities potentially prevented by vaccination of infants and elderly persons with a proposed 26-
valent vaccine, Auckland, New Zealand, 2005–2006* 
Age group, y 
(no. emm typed) 
Assumed
vaccine
efficacy, % 
Assumed
vaccine
coverage, % 
No. (%) persons with GAS 
disease from emm types in 
the 26-valent vaccine†
GAS-related deaths 
from emm type in the 
26-valent vaccine†, %
Potential GAS 
disease
prevented %‡ 
Potential GAS-
related deaths 
prevented, %§ 
<5 (25)  >84 80¶ 11 (44)  1# 29.6 0.67
>65 (59)  84 60** 18 (30.5)  14 (1/7)  15 7.1
*GAS, group A streptococcal. 
†Among patients with typed isolates. 
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